Vanda Pharmaceuticals (NASDAQ:VNDA) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald boosted their price target on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Down 1.5 %

Vanda Pharmaceuticals stock opened at $4.67 on Monday. Vanda Pharmaceuticals has a 52-week low of $3.30 and a 52-week high of $6.75. The firm has a market capitalization of $272.21 million, a price-to-earnings ratio of -58.38 and a beta of 0.77. The company has a fifty day simple moving average of $5.28 and a 200-day simple moving average of $5.15.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $50.47 million for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. On average, research analysts anticipate that Vanda Pharmaceuticals will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. SageView Advisory Group LLC acquired a new position in Vanda Pharmaceuticals in the first quarter valued at about $34,000. Meeder Asset Management Inc. acquired a new position in Vanda Pharmaceuticals in the second quarter valued at about $39,000. China Universal Asset Management Co. Ltd. lifted its position in Vanda Pharmaceuticals by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 4,387 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Vanda Pharmaceuticals during the second quarter worth about $61,000. Finally, Price T Rowe Associates Inc. MD increased its stake in Vanda Pharmaceuticals by 18.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 2,425 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.